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Consecutive cases of human infection with H7N9 influenza viruses since 2013 in China 
have prompted efforts to develop an effective treatment. Subunit vaccines introduced by 
intranasal administration can block an infection at its primary site; flagellin (fliC) and poly-
ethyleneimine (PEI) have been shown to be potent adjuvants. We previously generated 
the hemagglutinin (HA)1–2-fliC fusion protein consisting of the globular head domain 
(HA1–2; amino acids 62–284) of HA fused with Salmonella typhimurium fliC. In the pres-
ent study, we investigated its effectiveness of both flagellin and PEI as mucosal adjuvants 
for the H7N9 influenza subunit vaccine. Mice immunized intranasally with HA1–2-fliC 
and HA1–2-PEI showed higher HA1–2-specific immunoglobulin (Ig)G and IgA titers in 
serum, nasal wash, and bronchial alveolar lavage fluid. Moreover, splenocyte activation 
and proliferation and the number of HA1–2-specific interferon (IFN)-γ- and interleukin 
(IL)-4-producing splenocytes were markedly increased in the fliC and PEI groups; in the 
latter, there were more cells secreting IL-4 than IFN-γ, suggesting that fliC induced T 
helper type (Th)1 and Th2 immune responses, and PEI induced Th2-biased responses, 
consistent with the serum antibody isotype pattern (IgG1/IgG2a ratio). Furthermore, 
virus challenge was performed in a chicken model. The results showed that chickens 
receiving fliC and PEI adjuvant vaccine exhibited robust immune responses leading to a 
significant reduction in viral loads of throat and cloaca compared to chickens receiving 
only HA1–2. These findings provide a basis for the development of H7N9 influenza 
HA1–2 mucosal subunit vaccines.
Keywords: avian influenza a (h7n9) virus, hemagglutinin globular head, flagellin, polyethyleneimine, mucosal 
subunit vaccine
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inTrODUcTiOn
In the spring of 2013, an H7N9 subtype of avian influenza virus 
infecting humans was discovered in China; although initially the 
virus replicated silently in chickens without causing disease (1), 
rapid development throughout the country led to an outbreak. 
Despite a lot of work to control the infection, H7N9 influenza 
viruses have continued to spread, leading to human infections 
in many provinces of inland China, Taiwan, and Hong Kong, 
with 212 of the 571 confirmed cases proving fatal as of February 
23, 2015 (2). To date, there exist no licensed vaccines for H7N9 
infection. Therefore, it is critical to develop a vaccination strategy 
to protect against H7N9 influenza.
Vaccination is one of the most efficacious and cost-effective 
medical interventions. The advantage of subunit vaccines is that 
they provide a safe and specific stimulus for the induction of 
immunity (3). The administration of antigen to mucosal surfaces is 
possibly the best method of inducing mucosal immune responses 
at distant as well as local sites (4), and efforts are on the way to 
develop mucosal vaccines for influenza (5, 6). A main obstacle 
to mucosal subunit vaccines has been the lack of an appropriate 
adjuvant; the only one licensed for human use (aluminum) is 
unsuitable for mucosal applications (3).
Toll-like receptors (TLRs) are a family of receptors that rec-
ognize pathogen-associated molecular patterns on cells of the 
innate immune system and play a key role in responding and 
determining to microbial infections. Molecular adjuvants based 
on TLR ligands have been shown to enhance the immunogenicity 
of vaccines, and these ligands are increasingly recognized as key 
adjuvant targets (7). Flagellin, a TLR5 ligand, is also known to 
exhibit potent adjuvant effects on inducing immune response 
(8, 9). Our previous study showed that hemagglutinin (HA)1–2 
of H7N9 influenza virus fused to Salmonella typhimurium fliC 
induced robust immune responses in mice immunized intraperi-
toneally (10, 11). Influenza subunit vaccines based on HA1–2 
and flagellin have been shown to exert protective effects in other 
studies (12, 13), suggesting that HA1–2 is a promising subunit 
vaccine candidate. However, in these studies, mice were immu-
nized subcutaneously or intraperitoneally; there are few reports 
describing the use of flagellin as a mucosal adjuvant in influenza 
subunit vaccines (14).
A recent study found that polyethyleneimine (PEI) has potent 
mucosal adjuvant activity for viral subunit soluble glycoprotein 
antigens, including gp140 derived from human immunode-
ficiency virus 1 and HA protein from influenza virus (15). We 
speculated that intranasal immunization with PEI combined 
with HA1–2 of H7N9 influenza virus could improve mucosal and 
systemic immunity.
In this study, we used fliC and PEI as mucosal adjuvants for 
H7N9 influenza HA1–2 subunit vaccine, with cholera toxin B 
subunit (CTB) used as a positive control. HA1–2-fliC and HA1–
2-PEI increased immunoglobulin (Ig)G and IgA production in 
serum, nasal wash, and bronchial alveolar lavage fluid (BALF) 
as well as the number of HA1–2-specific interferon (IFN)-γ- and 
interleukin (IL)-4-producing splenocytes. Mice vaccinated intra-
nasally with candidate adjuvant-based influenza subunit vaccines 
developed rapid systemic and robust local mucosal immune 
responses. In addition, chickens receiving flagellin and PEI 
adjuvant candidate vaccines exhibited robust immune responses 
with decreased viral loads in throat and cloaca following H7N9 
influenza virus challenge.
MaTerials anD MeThODs
ethics statement
Female C3H/HeJ mice (a spontaneous mutation in TLR4 
gene) aged 6 weeks were purchased from the SLAC Laboratory 
Animal Co. Ltd., Shanghai, China. We used C3H/HeJ mice as 
a model ruling out the role for TLR4 responses in the adjuvant 
activity. Two-week-old specific-pathogen-free (SPF) White 
Leghorn chickens were purchased from poultry institute, 
Shandong academy of agricultural science. All mice and birds 
were housed in isolators and kept in a room with controlled 
temperature, light, and ventilation. Pathogen-free water and 
diet were supplied ad  libitum. All animal studies were per-
formed in accordance with the Committee on the Ethics of 
Animal Experiments of Yangzhou University (Approval ID: 
SYXK [Su] 2012–0029).
Viruses
The avian influenza H7N9 virus (A/chicken/Jiangsu/CZT4/2013) 
used in this study was provided by the Animal Infectious Disease 
Laboratory of Yangzhou University. The inactivated virus using 
0.1% formalin was used as hemagglutination inhibition (HAI) 
antigen, and the live virus was used in the viral challenge 
experiment.
Preparation of candidate Vaccines
Recombinant His-tagged HA1–2 and HA1–2-fliC proteins were 
prepared as previously described (10). HA1–2-PEI candidate 
vaccine was prepared at least 2 h before vaccination by mixing 
the antigen to a pre-diluted PEI solution (25-kDa branched form; 
Sigma-Aldrich, St. Louis, MO, USA) (11). CTB adjuvant (Sigma-
Aldrich) was mixed with purified HA1–2 protein just prior to 
immunization.
nasal Vaccination and sampling
C3H/HeJ mice (n =  6) were lightly anesthetized with Zoletil 
(Virbac, Carros, France) (10 mg/kg body weight) and intrana-
sally vaccinated with a volume of 50 μl containing 10 μg HA1–2, 
30  μg HA1–2-fliC (containing 10  μg HA1–2), 10  μg HA1–2 
mixed with 20 μg PEI, 20 μg CTB in phosphate-buffered saline 
(PBS), or 50  μl PBS, respectively, on days 0, 14, and 28. The 
volume of 50 μl was administered dropwise to external nares 
of the mice (25 μl per nostril) using a micropipette. Animals 
were bled 12  days after the second and third immunizations. 
Serum samples were analyzed by HAI assay and enzyme-linked 
immunosorbent assay (ELISA) to detect the HA1–2-specific IgA 
and IgG titers and its subtypes (IgG1 and IgG2a). Two weeks 
after the last immunization, nasal wash and BALF were collected 
by washing the organs three times with 0.2 or 0.5 ml sterile PBS, 
respectively, and secretory IgA and IgG levels were determined 
by ELISA (Figure 1).
FigUre 1 | Vaccination and blood sample collection schedule. C3H/
HeJ mice (n = 6 per group) were vaccinated intranasally with three doses of 
PBS, HA1–2, HA1–2-fliC, or HA1–2 combined with PEI or CTB on days 0, 
14, and 28. Animals were bled on days 26 and 40 following the second and 
third immunizations. Resultant serum samples were used to assess serum 
antibody responses, and all mice were sacrificed on day 42 to evaluate 
cellular immune responses.
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enzyme-linked immunosorbent assay
Antigen-specific IgG, IgG1, IgG2a, and IgA in serum and IgA and 
IgG in lavage fluid were detected by indirect ELISA as previously 
described (10). Briefly, 96-well plates were coated with 2.5  μg/
ml glutathione S-transferase-tagged HA1–2 antigen in 50  mM 
carbonate buffer (pH 9.6) at 4°C overnight. After washing and 
blocking, samples at twofold dilution were added for 2 h at 37°C. 
Horseradish peroxidase-conjugated goat anti-mouse IgA (1:2,000), 
IgG (1:10,000), IgG1 (1:3,000), or IgG2a (1:3,000) (Invitrogen, 
Carlsbad, CA, USA) was added by incubation for 1 h at 37°C, with 
3, 3′, 5, 5′-tetramethybenzidine used as a substrate. The reaction 
was terminated with 2 M H2SO4, and the absorbance at 450 nm was 
read on a microplate reader (BioTek, Winooski, VT, USA). The 
cutoff value was defined as the mean + 2 SD of negative control. 
The antibody titers were defined as the reciprocal of the highest 
dilution of samples that had a reading above the cutoff value.
hai assay
Animals were bled 12 days after the third immunizations. Serum 
samples were analyzed by HAI assay, which were conducted 
according to our previously described procedure (10).
isolation of splenic lymphocytes
Two weeks after the third immunization, splenic lymphocytes 
were obtained from the spleens of mice by density gradient 
centrifugation using Lymphoprep (specific gravity 1.077) (Sigma-
Aldrich) according to the manufacturer’s instructions. Single-
splenocyte suspensions were prepared in complete Roswell Park 
Memorial Institute (RPMI) 1640 medium plus 1% penicillin-
streptomycin/l-glutamine and 10% fetal bovine serum (Gibco, 
Carlsbad, CA, USA) at a final concentration of 2 × 106 cells/ml.
cell Proliferation elisa Based on Bromo-
2′-Deoxyuridine (BrdU)
Splenic lymphocytes were obtained from each mouse after the 
third vaccination as described above, and the cell proliferation 
assay of splenic lymphocyte pre-treated with 10 μg/ml of HA1–2 
was performed using the commercially available ELISA Kit based 
on 5-BrdU (Roche Diagnostics, Tokyo, Japan) according to the 
manufacturer’s protocol.
iFn-γ and il-4 enzyme-linked 
immunospot (elisPOT) assays
Splenic lymphocytes were obtained from mice after the third vac-
cination, and the single-splenocyte suspensions were prepared for 
quantifying HA1–2-specific IFN-γ- or IL-4-producing cells using 
the BD ELISPOT set (BD Biosciences, Franklin Lakes, NJ, USA). 
All ELISPOT assays were performed according to our previously 
described procedure (11).
histological analysis
Groups of C3H/HeJ mice (n  =  3) were anesthetized with 
Zoletil (Virbac) and vaccinated intranasally with one dose of 
the candidate vaccines. At 12-h postvaccination, the mice from 
each group were sacrificed, and the left lungs and trachea were 
removed and fixed in 10% neutral formalin at room temperature 
for 48 h. Serial tissue sections (4 μm thick) were prepared and 
stained with hematoxylin and eosin (H&E) for histological 
analysis.
chicken Vaccination and Viral challenge
A total of 70 SPF chickens at 2-week-old were randomized into 5 
groups (n = 14). Prior to challenge, all birds were immunized, and 
the immunization dosage and programs were the same as mice 
vaccination. In each group, the birds were immunized intranasally 
with a final volume of 100 μl/dose/chicken candidate vaccines on 
days 0, 14, and 28. At 2 weeks after the third immunization (on 
day 42), chickens (n = 6) in each group were bled from the wing 
vein and sacrificed for immune response determination. The oth-
ers (n = 8) were inoculated intranasally with 106 50% egg infec-
tious dose (EID50) of H7N9 influenza virus in a 200 μl volume. 
The throat and cloaca swabs were collected from chickens at 3, 5, 
and 7 day postinoculation (dpi) and resuspended in 1 ml PBS for 
viral RNA extraction followed by real-time PCR (RT-PCR) for 
quantitative analysis of virus.
Quantitative analysis of Viral load
Viral RNA was extracted from the swab samples of chicken 
using TIANamp Virus RNA Kit (TianGen, Beijing, China). 
cDNA was synthesized from mRNA using a PrimeScrip RT 
reagent Kit (TaKaRa, Dalian, China) according to the manu-
facturer’s instructions. For viral quantification, the primers 
forward: 5′-GGAGTTCTAATTATCAACAATC-3′; reverse: 
5′-TCCCATAGATTTTCCTCTC-3′; and the TaqMan probe: 
5′-(FAM) CCAGGAGCGAGACCACAAGTTA (TAMRA)-3′ 
were designed to amplify and detect a 185-base pair segment 
of HA gene of H7N9 influenza virus. The reaction was run on 
an ABI 7500 with the following steps: 95°C for 30 s, followed 
by 40 cycles of 95°C for 5 s and 60°C for 34 s. Data analyses 
were performed using the 7500 software supplied with the 
instrument. The copy number of the HA gene was calculated 
on the basis of a standard curve using an HA-containing 
plasmid pCold-HA1–2 (10) of known concentration as a 
standard. The copy numbers of the HA gene were quantified 
by the following equation: copies/μl =  [(6.02 ×  1023 copies/
mol) × concentration of plasmid g/μl]/(number of base pairs 
of the plasmid × 2 × 324.5).
FigUre 2 | antibody response in serum. C3H/HeJ mice (n = 6 per group) were vaccinated intranasally with three doses of HA1–2, HA1–2-fliC, PBS, or HA1–2 
combined with PEI or CTB. Animals were bled 12 days after the second and third immunizations. Antibody titers were measured by ELISA or hemagglutination 
inhibition (HAI) assay. (a) HA1–2-specific IgG titers after the second and third immunizations. (B) HA1–2-specific IgA titers after the third immunizations. (c) HAI 
titers after the third immunizations.
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statistical analysis
Data are expressed as mean ± SEM unless otherwise stated. The 
differences between groups were analyzed using Mann–Whitney’s 
U test with a 95% confidence interval (SPSS 16.0). P < 0.05 was 
regarded as significant.
resUlTs
antibody response in serum
Mice were vaccinated intranasally with HA1–2, HA1–2-fliC, 
or HA1–2 combined with PEI or CTB on days 0, 14, and 28 
(Figure 1). The capacity of these candidate vaccines to induce a 
humoral immune response was evaluated by detecting the presence 
of HA1–2-specific antibodies in the serum by ELISA at 12 days post 
the second and third vaccination. HA1–2-specific IgG titers were 
higher after the third as compared to after the second immunization 
(>10,000 vs. ≈3,000). HA1–2-fliC and HA1–2-PEI elicited higher 
IgG titers than HA1–2 alone (Figure 2A). Similarly, HA1–2-specific 
IgA titers in serum induced by HA1–2-fliC and HA1–2-PEI (340 
and 480 on average, respectively) after the third immunization were 
higher than that of HA1–2 alone (66.6 on average) (Figure 2B).
In addition, HAI titers in the adjuvant groups following the 
third immunization were about fourfold to sixfold higher than 
in animals immunized with HA1–2 antigen alone (29.3 for PEI, 
40 for HA1–2-fliC, and 6.6 for HA1–2) (Figure  2C). The fliC 
and PEI adjuvant group elicited superior immune responses and 
induced similar HAI titers compared to the positive control.
ha1–2-specific igg subtype responses to 
candidate Vaccines
The IgG subtype (IgG1 and IgG2a) induced in each group was 
assessed by ELISA, and the IgG1/IgG2a ratio was calculated. 
A ratio of 0.5 or less indicates a T helper type (Th)1-biased 
response. A ratio of 2.0 or more indicates a Th2-biased response. 
Ratios between 0.5 and 2.0 indicate a mixed or balanced 
response (16). In the group immunized with PEI-supplemented 
vaccine, the IgG1 titer was significantly higher than the IgG2a 
titer (P < 0.05). The highest IgG1/IgG2a ratio (7.6) was observed 
in the group immunized with PEI-supplemented vaccine, while 
the ratio was lower in the HA1–2-fliC group (0.9) and similar 
to that observed for CTB (1.2) vaccine and HA1–2 alone (1.5) 
(Figure 3).
FigUre 3 | ha1–2-specific igg subtype responses to candidate 
vaccines. C3H/HeJ mice (n = 6 per group) were vaccinated intranasally with 
three doses of HA1–2, HA1–2-fliC, PBS, or HA1–2 combined with PEI or 
CTB. Animals were bled 12 days after the third immunization and HA1–2-
specific IgG subtype (IgG1 and IgG2a) titers were measured by ELISA.
FigUre 4 | antibody responses in nasal wash and bronchial alveolar lavage fluid (BalF). HA1–2 specific IgG and IgA titers were induced by intranasal 
immunization with candidate vaccines. (a–D) Nasal wash and BALF samples were collected 2 weeks after the last immunization, and HA1–2-specific IgA and IgG 
titers in nasal wash (a,c) and BALF (B,D) of immunized mice (n = 6) were measured by ELISA.
5
Song et al. Mucosal Adjuvants for Influenza Vaccines
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 326
antibody response in nasal Wash 
and BalF
The amount of IgA secreted by the mucosa is used as an index 
of mucosal immune response (17). To determine whether PEI 
and fliC are effective adjuvants in the mucosal immune response, 
nasal wash and BALF of mice immunized three times with candi-
date vaccines were obtained by three successive PBS washes, and 
HA1–2-specific IgA and IgG levels were determined by ELISA. 
Compared to HA1–2 alone, HA1–2-specific IgA as well as IgG 
levels in the nasal wash and BALF were increased in HA1–2-PEI 
and HA1–2-fliC groups (Figure  4). HA1–2-fliC immunization 
induced higher HA1–2-specific nasal and BAL mucosal IgA titers 
(280, P < 0.05 and 187, P < 0.05, respectively) than HA1–2 immu-
nization (30 and 19 on average, respectively). Similarly, HA1–2-
PEI stimulated nasal and BAL mucosa to induce higher IgA titers 
(240, P < 0.05 and 120, P < 0.05, respectively) (Figures 4A,B). 
Moreover, nasal and BAL mucosal IgG titers induced by 
HA1–2-fliC (500, P < 0.01 and 480, P < 0.01, respectively) and 
FigUre 5 | splenocyte stimulation index (si). Splenocytes were prepared 
from the spleens of mice after the third immunization, and the SI of cells in 
response to purified HA1–2 (10 μg/ml) protein was calculated based on cell 
proliferation, as determined with the BrdU assay, using the following equation: 
SI = (OD450 − OD690 of antigen-treated cells)/(OD450 − OD690 of untreated cells).
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HA1–2-PEI (280, P < 0.01 and 340, P < 0.01, respectively) were 
also significantly higher than HA1–2 immunization (46 and 67 
on average, respectively) (Figures 4C,D).
cellular immune response in spleen
All vaccinated mice were euthanized 14  days after the third 
immunization. Splenic lymphocytes were isolated from vacci-
nated mice and stimulated with HA1–2 for 48 h, and the cellular 
immune response was assessed with the BrdU assay. Compared 
to the response of mice treated with HA1–2 alone (1.6 on aver-
age), the fliC- and PEI-supplemented groups showed significantly 
higher stimulation index (2.5, P < 0.05 and 2.7, P < 0.05, respec-
tively) (Figure 5).
iFn-γ- and il-4-Producing cells induced 
by candidate Vaccines
To further evaluate the ability of vaccine candidates to induce 
cellular immune responses and to estimate the immune types, 
ELISPOT assays were performed to determine the numbers 
of cells secreting IFN-γ and IL-4. Splenic lymphocytes were 
prepared 2  weeks after the third immunization and stimulated 
with HA1–2 in vitro. The average numbers of IFN-γ- and IL-4-
producing cells were higher in HA1–2-fliC (26, P < 0.05 and 25, 
P < 0.05, respectively) and PEI-supplemented (25, P < 0.05 and 
34, P <  0.01, respectively) vaccine groups than in the HA1–2 
vaccine group (14 and 13, respectively). Notably, a significantly 
greater number of IL-4- than IFN-γ-producing cells were induced 
by PEI-supplemented vaccine (P < 0.05) (Figure 6), indicating 
that Th2-biased immune responses were induced by PEI-
supplemented vaccine. In contrast, equal numbers of IFN-γ- and 
IL-4-producing cells were observed in the HA1–2-fliC group, 
indicating that both Th1- and Th2-associated immune responses 
were induced by the vaccination.
histological analysis of Trachea and lung
Formalin-fixed, paraffin-embedded lung and trachea sections 
from groups of three mice were prepared at 12  h and stained 
with H&E. The intact structures were observed in trachea and 
lung sections from all groups of mice vaccinated with candidate 
vaccines or PBS. No evidence of any tissue damage was observed. 
Moreover, sections of trachea and lung from mice vaccinated 
with HA1–2-fliC and HA1–2-PEI showed activated immune 
responses with a number of neutrophils around the trachea or 
into the tracheal cavity compared to control sections (Figure 7).
Virus loads in Throat and cloaca of h7n9 
Virus challenged chickens
Prior to challenge, the results showed that chickens vaccinated 
with HA1–2-fliC and HA1–2-PEI could elicit significantly 
FigUre 6 | Quantitative analysis of interferon (iFn)-γ- and interleukin (il)-4-producing cells. On day 42, mice (n = 6) were euthanized and single-cell 
suspensions prepared from the spleens were cultured for 48 h, then stimulated with purified protein HA1–2 (5 μg/ml). IFN-γ and IL-4 secretion was detected in 
triplicate with the ELISPOT assay.
7Song et al. Mucosal Adjuvants for Influenza Vaccines
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 326
increased serum IgG, nasal wash and BALF IgA titers compared 
to that vaccinated with HA1–2 (Figure S1 in Supplementary 
Material). In order to investigate whether flagellin and PEI 
could improve the protective efficacy of HA1–2, we detected 
the viral loads in throat and cloaca of H7N9 virus challenged 
chickens. The copy numbers of the HA gene were determined 
using RT-PCR with an HA-containing plasmid of known 
concentrations (Figure 8C). At 3 dpi, the average virus loads 
in throat and cloaca of chickens vaccinated with HA1–2-fliC 
were significantly reduced (52, P <  0.001, and 15, P <  0.001, 
respectively) compared to chickens vaccinated with HA1–2 
(225 and 137, respectively). Similarly, the average levels of 
virus were also significantly decreased in PEI-vaccinated 
chickens (12, P <  0.001, and 28, P <  0.001, respectively). At 
5 dpi, significantly lower virus loads were observed in cloaca 
in HA1–2-fliC (51, P <  0.001) and PEI-adjuvant group (58, 
P < 0.05) compared to chickens vaccinated with HA1–2 (157 
on average) (Figures 8A,B).
DiscUssiOn
Inactivated vaccines are typically administered via the subcuta-
neous or intramuscular route to prevent influenza virus infection 
(18, 19). Although these vaccines induce serum IgG antibodies, 
they induce poor IgA at respiratory mucosal sites. In addition, 
an intranasal vaccine would be easier to administer than an 
intramuscular vaccine and could have fewer adverse effects, 
thereby more people may be willing to be vaccinated (20, 21). This 
study was carried out in order to improve the immunogenicity 
of a nasally administered influenza HA1–2 subunit vaccine that 
would induce both systemic and mucosal antibody responses.
To determine the capacity of candidate vaccines to induce 
humoral immunity, we measured HA1–2-specific antibody 
responses in serum. Higher IgA and IgG titers were detected in 
the HA1–2-fliC and HA1–2-PEI than in the HA1–2 group, which 
were similar to those observed by intraperitoneal immunization 
(10). The serum IgA titer was less robust but was elevated com-
pared to HA1–2 without adjuvant. It has been reported that serum 
HAI titers are correlated with the degree of protection conferred 
by inactivated influenza vaccines administered intramuscularly 
or subcutaneously, and they therefore serve as the standard for 
evaluating these vaccines in adults (22, 23). We evaluated the 
ability of serum IgG antibodies to neutralize the influenza virus 
in supplemented vaccine groups and found that all animals in 
these groups had higher HAI titers (1:40) than the HA1–2 group.
IgA provides the greatest immunological defense against 
microbial infection at the mucosal surface and is considered an 
important indicator of mucosal immunity (16). Since the nasal 
cavity and bronchial alveoli comprise a large surface area of 
mucous membrane, IgA and IgG levels were measured in nasal 
wash and BALF 2 weeks after the last vaccination. IgG titers were 
increased at the mucosal surface, and IgA levels were higher 
in mice vaccinated with HA1–2-fliC and HA1–2-PEI than in 
those without adjuvant treatment. Additionally, previous study 
has showed that intranasal administration of influenza vaccines 
induces higher virus-specific IgA and IgG2a responses in mice 
than that by subcutaneous administration (24), which empha-
sized the importance of intranasal route in vaccination against 
influenza.
The ideal vaccine stimulates serum IgG and mucosal IgA 
production, a cytokine response, and a longer-lasting immune 
response (25). We found that mice vaccinated with HA1–2-fliC 
and HA1–2-PEI developed a rapid systemic immune response in 
serum and robust mucosal immune response in the nasal cavity 
and bronchial alveoli. T cells play an important role in protec-
tion against various strains of influenza virus (26). We evaluated 
proliferation and cytokine secretion in splenocytes following 
HA1–2 stimulation in vitro. As expected, cell proliferation was 
FigUre 7 | histological analysis. C3H/HeJ mice (n = 3) were vaccinated intranasally with one dose of PBS, HA1–2, HA1–2-fliC, or HA1–2 combined with PEI. 
The lungs and trachea were removed from mice at 12-h postvaccination, and tissue sections were prepared and stained with H&E for histological analysis (100× 
magnification).
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increased, which was consistent with previous study showing 
that a significant increase of PMBC proliferation was observed 
in chickens vaccinated with mFliC or pFliC-adjuvanted vaccines 
(27), yielding higher numbers of IFN-γ- and IL-4-producing cells 
in the adjuvant groups than in mice administered the HA1–2 vac-
cine, suggesting that antigen-specific lymphocytes were activated 
in the spleen.
Cluster of differentiation 4-positive Th differentiates into Th1 
and Th2 subtypes, which are associated with primarily cellular 
immune responses and antibody production, respectively (28). 
HA1–2-fliC and PEI-supplemented vaccines induced higher 
numbers of spleen cells to secrete IL-4 and IFN-γ, whereas PEI 
induced more cells to secrete IL-4. In mice, IFN-γ and IL-4 are 
associated with Th1 and Th2 responses, respectively (25, 29). Thus, 
our data indicate that mice vaccinated with HA1–2-fliC exhibited 
a balanced Th1/Th2 response, and HA1–2-PEI exhibited a Th2-
biased response. These results reflected the pattern of antibody 
isotypes (IgG1/IgG2a); HA1–2-fliC induced a high level of IgG1 
and IgG2a antibodies, and the IgG1/IgG2a ratio was close to 1, 
indicating a balanced Th1/Th2-type immune response. This is in 
contrast to another study reporting that co-delivery of fliC with 
an antigen induced a Th2 response in mice (30). We speculate 
that mouse strain difference affect the immune response bias. 
It was recently reported that systemic delivery of branched PEI 
stimulated a mixed Th1/Th2-type adaptive immune response 
(31). In our study, the third dose of the HA1–2-PEI vaccine 
boosted serum IgG2a and IgG1 titers, producing a IgG1/IgG2a 
ratio ≥2.0, which indicated a Th2-biased immune response.
Mucosal vaccines have advantages for respiratory diseases, 
but one of the challenges is to identify a safe vehicle for intranasal 
delivery of influenza antigens to induce protective mucosal and 
serum antibody responses (32). In our study, the cationic polymer 
PEI was used to overcome barriers to intranasal administration. 
We found that PEI could be used as an adjuvant for a mucosal 
influenza vaccine when administered intranasally with influenza 
HA1–2 antigen. PEI was recently reported to stimulate mixed 
T-cell responses in mucosa (15, 33) and could be modified to 
target dendritic cells, which are professional antigen-presenting 
cells that express high levels of surface mannose receptor (29). 
Additionally, safety evaluation of HA1–2-fliC and HA1–2-PEI 
candidate vaccines was performed in this study. No tissue damages 
of lung and trachea were observed in vaccinated mice. A number of 
neutrophils appeared around the trachea or into the tracheal cavity 
from mice vaccinated with HA1–2-fliC and HA1–2-PEI, which 
was consistent with the results of other studies that flagellin and 
PEI could induce innate immunity as vaccine adjuvants (15, 34).
FigUre 8 | Viral loads detection in throat and cloaca following h7n9 virus challenge of vaccinated chickens. Two-week-old SPF chickens (n = 8) were 
inoculated intranasally with 106 EID50 of H7N9 influenza virus in a 200 μl volume. The throat and cloaca swabs were collected from chickens and resuspended in 
1 ml PBS for viral RNA extraction followed by real-time PCR (RT-PCR) for quantitative analysis of virus. (a) Viral loads in throat following H7N9 virus challenge at 
3 dpi. (B) Viral loads in cloaca following H7N9 virus challenge at 3 and 5 dpi. (c) Standard curves (based on plasmid DNA) indicating the linearity and efficiency for 
detecting HA by RT-PCR.
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